Product image of Ivabradina Combix (Ivabradine) supplied by GNH India

Ivabradina Combix

Active Ingredient:
Ivabradine
Origin:
EU

Ivabradina Combix (Ivabradine)

Ivabradine, the active ingredient in Ivabradina Combix, is an If channel inhibitor presented as an oral tablet for oral administration. It selectively reduces heart rate without affecting contractility, making it suitable for patients with chronic stable angina and heart failure with reduced ejection fraction.

GNH India supplies Ivabradina Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, sourced from the European Union market and meeting EU quality standards.

Manufacturer / TM Owner

Laboratorios Combix, S.L.U.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ivabradina Combix acts on the cardiac If current to manage specific cardiovascular conditions.

  • Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate.
  • Heart failure with reduced ejection fraction: improves symptoms and may lower hospitalization risk by decreasing myocardial oxygen demand.
  • Patients intolerant to beta‑blockers: provides heart‑rate control when beta‑blockers are contraindicated or not tolerated.

How It Works

  • Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, which slows depolarisation of pacemaker cells. This action reduces spontaneous heart‑rate generation without impairing myocardial contractility or blood pressure, leading to a lower cardiac workload and oxygen consumption.

Side Effects

Adverse reactions may occur with Ivabradina Combix and are reported in clinical use.

Common Side Effects

  • Bradycardia: resting heart rate falls below the intended range.
  • Visual disturbances: luminous phenomena or phosphenes.
  • Headache.
  • Dizziness.
  • Fatigue.
  • Nausea.

Serious or Rare Side Effects

  • Severe bradycardia requiring medical intervention.
  • Atrial fibrillation or other arrhythmias.
  • Symptomatic hypotension.
  • Visual loss or retinal abnormalities.
  • Heart block (second‑ or third‑degree).
  • Anaphylactic or severe allergic reactions.

Precautions & Warnings

Before prescribing Ivabradina Combix, clinicians should consider several safety measures.

  • Monitor heart rate: ensure resting heart rate remains above 50 bpm.
  • Avoid in severe hepatic impairment: dose adjustment may be required.
  • Caution in sick‑sinus syndrome or atrioventricular block: contraindicated in high‑grade block.
  • Review concomitant bradycardic agents: beta‑blockers or digoxin may amplify effects.
  • Adjust in renal impairment: use with caution in moderate to severe renal dysfunction.
  • Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture.

Avoid Interactions

Ivabradina Combix can interact with other medicines, influencing its safety and efficacy.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole): may increase ivabradine plasma levels.
  • Other bradycardic agents (beta‑blockers, digoxin, diltiazem): risk of excessive heart‑rate reduction.
  • Certain antiarrhythmic drugs (e.g., amiodarone): can potentiate bradycardia.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may modestly raise concentrations.
  • CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.
  • Other anti‑anginal medications (nitrates, calcium‑channel blockers): monitor for additive hypotensive effects.

Frequently Asked Questions

Ivabradina Combix contains ivabradine, which is prescribed to lower heart rate in patients with chronic stable angina and in those with heart failure with reduced ejection fraction. By reducing the heart’s pacing activity, it helps relieve chest pain and improves functional capacity in heart‑failure patients.

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the primary pacemaker of the heart. Inhibition of this current slows the spontaneous depolarisation of pacemaker cells, leading to a lower resting heart rate while preserving myocardial contractility and blood pressure.

The dose of Ivabradina Combix is individualized by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and tolerance. The prescriber determines the appropriate strength, frequency, and any necessary adjustments.

Safety data for ivabradine in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and decisions are made by the treating physician in consultation with the patient.

To request Ivabradina Combix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by directly inhibiting the If current without affecting beta‑adrenergic receptors. This means it does not influence blood pressure or contractility, making it useful when beta‑blockers are contraindicated, poorly tolerated, or insufficient alone.

Store Ivabradina Combix at ambient temperature, below 25 °C, in the original container to protect it from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Ivabradina Combix is taken orally, usually with a glass of water. It can be taken with or without food, but the dose should be taken at the same time each day to maintain consistent blood levels. Follow the prescribing clinician’s instructions.

The most serious adverse events include severe bradycardia, atrial fibrillation or other arrhythmias, symptomatic hypotension, visual disturbances that may progress to vision loss, and high‑grade heart block. Patients should seek immediate medical attention if they experience fainting, severe dizziness, or sudden visual changes.

Ivabradina Combix is contraindicated in patients with severe hypotension, sick‑sinus syndrome, second‑ or third‑degree atrioventricular block, acute myocardial infarction, or those taking strong CYP3A4 inhibitors that cannot be discontinued. It should also be avoided in individuals with known hypersensitivity to ivabradine.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ivabradine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT